Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New discoveries in age-related macular degeneration revealed in industry and academia

12.12.2014

Insilico Medicine along with scientists from Vision Genomics and Howard University shed light on AMD disease, introducing the opportunity for eventual diagnostic and treatment options.

The scientific collaboration between Vision Genomics, Inc., Howard University, and Insilico Medicine, Inc., has revealed encouraging insight on the AMD disease using an interactome analysis approach. Resources such as publicly available gene expression data, Insilico Medicine's original algorithm OncoFinderTM, and AMD MedicineTM from Vision Genomics allowed discovery of signaling pathways activated during AMD disease.

"We are thrilled to collaborate with Alex Zhavaronkov and Evgeny Makarev, and their team at InSilico Medicine. Big Data analysis is part of the future of medicine, and with our technique of signaling pathway activation analysis, we will decipher the genetic network alterations that lead to age-related macular degeneration (AMD), and eventually human aging itself", said Antonei Benjamin Csoka, PhD, CEO of Vision Genomics, LLC, and Assistant Professor at Howard University.

The research publication titled "Pathway activation profiling reveals new insights into Age-related Macular Degeneration and provides avenues for therapeutic interventions" was accepted by one of aging research's top-rated journals "Aging", detailing these findings and methodology. This study not only validates the efficacy of interactome analysis within aging, but also allows the investigation of cellular populations within AMD models.

"We are happy to collaborate with Antonei Benjamin Csoka's teams at both Vision Genomics and Howard University on this exciting project. Coupling Big Data with advanced signaling pathway activation analysis may help find new therapeutic approaches for age-related macular degeneration (AMD), a disease that holds many keys to understanding human aging", said Evgeny Makarev, PhD, Director of Aging Research at Insilico Medicine.

On December 9th Insilico Medicine, Inc announced the appointment of 2013 Nobel Laureate in Chemistry, Michael Levitt, to its Scientific Advisory Board. Dr. Levitt's background in computational modeling focused on understanding protein folding processes and molecular interactions, may turn to be extremely valuable for compound discovery related to AMD and other age-related diseases.

The concept utilized by Insilico Medicine involves identifying the difference between several signaling states on a tissue-specific level, be it health and disease, or young and old, and evaluating a large number of drugs and drug combinations that can modulate the difference using advanced parametric and machine-learned algorithms.

"To create more value from our predictions we will need to identify compounds that are even more effective than top-scoring drugs and that would require multi-scale modeling of macromolecules, the field pioneered by Dr. Michael Levitt ", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. Insilico Medicine continues to be represented from top institutions, including Stanford University, Johns Hopkins University, and New York University. With this broad range of expertise, Insilico and its collaborators will pursue AMD disease further and utilize the newly discovered activated pathways as a foundation.

About Insilico Medicine

Insilico Medicine is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing for aging and age-related diseases. The company uses the GeroScope™ and OncoFinder™ packages for aging and cancer research. Through internal expertise and extensive collaborations with brilliant scientists, institutions, and highly credible pharmaceutical companies, Insilico Medicine seeks to discover new drugs and drug combinations for personalized preventative medicine.

For more information on Insilico Medicine, Inc. please visit http://www.insilicomedicine.com

Please contact:

Michael Petr
Market Research Associate
michael.petr@insilicomedicine.com

Michael Petr | EurekAlert!

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

Nonstop Tranport of Cargo in Nanomachines

20.11.2018 | Life Sciences

Researchers find social cultures in chimpanzees

20.11.2018 | Life Sciences

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>